🔎 Trials Near Me

Home › Neuroblastoma

Pag-aaral pangklinika para sa Neuroblastoma na nagre-recruit sa U.S.

47 pag-aaral para sa Neuroblastoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.

Mga lungsod na may pinakamaraming pag-aaral

Ayos sa estado

Mga pag-aaral na kamakailan lamang in-update

Opisyal na teksto ng pag-aaral (English)

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
4 Weeks · Lahat ng kasarian · Na-update Set 28, 2026 · NCT01109394

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

Nagre-recruitPhase 1
Edad 3 hanggang 35 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06995872

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Nagre-recruitPhase 3
Hanggang edad 30 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06172296

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Nagre-recruitObservasyonal na pag-aaral
Edad 4 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT01005654

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06395103

Biomarkers of Resiliency In Childhood Cancer Surgery

Nagre-recruitObservasyonal na pag-aaral
Edad 3 hanggang 25 · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06674811

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Nagre-recruitPhase 2
Hanggang edad 22 · Lahat ng kasarian · Na-update Set 4, 2026 · NCT02559778

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Nagre-recruitPhase 1/2
Hanggang edad 30 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06541262

B7-H3.CD28Z.CART in Solid Tumors

Nagre-recruitPhase 1
9 Months – 30 Years · Lahat ng kasarian · Na-update Set 3, 2026 · NCT07358260

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Nagre-recruitPhase 1/2
Hanggang edad 26 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06465199

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Nagre-recruitPhase 2
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06540963

International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE

Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Set 3, 2026 · NCT03088020

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Nagre-recruitPhase 2
18 Months – 19 Years · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT06528496

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Nagre-recruitPhase 3
365 Days – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03126916

Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma

Nagre-recruitPhase 2
Edad 1 hanggang 39 · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT07635056

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Nagre-recruitPhase 1
Edad 1 hanggang 23 · Lahat ng kasarian · Na-update Ago 13, 2026 · NCT07172958

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Nagre-recruitPhase 2
12 Months – 21 Years · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT05489887

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo
Lahat ng edad · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT04936529

SPEARHEAD-3 Pediatric Study

Nagre-recruitPhase 1/2
Edad 2 hanggang 21 · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT05642455

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Nagre-recruitPhase 2
Lahat ng edad · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT06057948

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Nagre-recruitPhase 1/2
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT06721689

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

Nagre-recruitPhase 1
Edad 1 hanggang 24 · Lahat ng kasarian · Na-update Hul 21, 2026 · NCT07211737

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Nagre-recruitPhase 2
Edad 1 hanggang 31 · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT06450041

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT07027748

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.